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OBJECTIVES: To demonstrate a simplified approach to cost-effectiveness analysis
of new diagnostic tests based on minimal information and without developing a
full decision-analytic modeling framework, which is often complex, time consum-
ing and potentially inefficient. METHODS: Using a simplified decision-analytic ap-
proach to the complete pathway of care from diagnosis to subsequent treatment,
cost-effectiveness of the new diagnostic test is expressed as a mathematical func-
tion of diagnostic accuracy, cost, burden, and the cost-effectiveness of treatment.
This function only includes parameters available during early test development
phases and does not require any simulation. Parameter uncertainty is accounted
for by applying probabilistic sensitivity analysis. In a clinical example, the cost-
effectiveness of magnetic resonance angiography (MRA) compared with digital
subtraction angiography (DSA) for the detection of new intracranial aneurysms is
assessed in patients with previous subarachnoid hemorrhage. RESULTS: The sim-
plified approach produced cost-effectiveness results for MRA compared with DSA
in line with our previous and similar, but much more comprehensive assessment.
The comprehensive assessment resulted in a net monetary benefit (NMB) of $1,910
(95%CI 1,809 to 5,565) and probabilities of effectiveness and cost-effectiveness of
98% and 87%, respectively (Willingness-to-pay threshold $50,000 per QALY). Our
simplified approach returned a NMB of $1,779 (95%CI 1,170 to 2,477) with corre-
sponding probabilities of effectiveness and cost-effectiveness of 100% and 98%,
respectively. Hence, the simplified approach would already have provided a clear
indication of the potential benefits of replacing DSA with MRA. CONCLUSIONS:
Given the abundance of new diagnostic tests an approximation of the cost-effec-
tiveness of new tests at minimal costs is highly valuable. Our low-cost mathemat-
ical satisficing approach supports improved use of health care resources by indi-
cating 1) which tests are promising; 2) which tests are not promising; and 3) which
tests require more rigorous economic evaluations to obtain improved estimates of
cost-effectiveness but at a higher use of health care resources.
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OBJECTIVES: To present an effective and elegant model approach to deal with
specific characteristics of complex modeling. METHODS: A discrete event simula-
tion (DES) model with multiple complications and multiple outcomes that each can
occur simultaneously was developed. In this DES model parameters, attributes and
distributions were estimated based on patient population (patient-level DES
model). Next to this, the DES model was constructed in such a way that it is par-
ticularly capable to deal with: different disease states, multiple complications, and
multiple long-term outcomes. Our model was designed for comparing two radia-
tion treatments (photon vs. proton) for head and neck cancer. In this model the
following elements were included: different disease states (local recurrency, dis-
tance metastasis, and combinations), simultaneous complications (xerostomia,
sticky saliva, dysphagia, and thyroid dysfunction), and multiple long-term out-
comes (overall survival, quality of life, costs). Estimates were based on the patient
population (n1013) treated with radiation therapy for head and neck tumor and
combined with literature based estimates. RESULTS: The following discrete events
were scheduled by a so-called statechart (system of graphical specification): pri-
mary tumor, mortality, time-to-event, and disease states. These events are sched-
uled with transitions following distributions that depend on tumor and other pa-
tient characteristics. In addition, the model contains a module for the primary
tumor prognosis, and separate, parallel modules/events for each important com-
plication. Costs and values of health for the different states/complications and
combined to cost-effectiveness are included. CONCLUSIONS: This elaborated DES
model allows multiple complications and outcomes to be modeled in parallel and
is suited to estimate the long-term effects. The global structure of our model can be
interesting for modeling other diseases that are associated with complex treat-
ment regimes and multiple complications. In addition, side effects in parallel to
main effects can be modeled and multiple outcomes of new pharmaceuticals com-
pared to current medication.
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OBJECTIVES: To identify the possible problems and trends regarding health eco-
nomic modelling in Hungarian Health Technology Assessment. We were especially
interested in the general quality of health economic models. METHODS: We ana-
lyzed the submissions which were based on a health economic model, which were
assessed by the Hungarian HTA Office since 2004. We created a database in which
we summed up our findings: the type of the model, the quality and robustness of
the model, the type of disease which was modelled. We sorted the models by these
criteria and searched for correlations. We attempted to set some indicators regard-
ing the quality of models. We also analysed some methodological and procedural
problems from multiple aspects related to modelling in Hungary. RESULTS: Our
findings show that the use of health economic models is increasing and that most
of the models are decision tree and Markov types. The submitted Markov models
are from the subtype of Markov chain models with only a few exceptions. Primarily
simulation models are only used in a small share of submissions (11%), especially
in the cases of chronic diseases. Trends show that the proportion of Markov models
which have probabilistic sensitivity analyses are also increasing (from 0% to nearly
30%). The submitted models became more detailed and they show a distinct im-
provement in methodology during the past 8 years. These factors indicate the
general improvement of the quality of Hungarian health economic modelling.
CONCLUSIONS: Although it is not compulsory in Hungary, more and more manu-
facturers present or submit health economic models to the Department of Health
Technology Assessment. Based on our findings, several factors indicate that the
submitted models are getting more detailed, and better of quality.
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OBJECTIVES: To compare the computation speed when running a microsimulation
model and probabilistic sensitivity analysis (PSA) on four widely-available pro-
gramming platforms: Excel, Visual Basic for Applications (VBA), R, and Java.
METHODS: A simple microsimulation model predicting the number of handouts
collected by 2500 ISPOR attendees during a congress was created to test efficiency
measured by model running speed. Speed was based on the system time and
included only the portion of code used to run the model, excluding any code for
parameter input or output. Calculations were performed on a computer running
Windows 7, dual core 2.6 GHz processor, with 4 GB RAM. All platforms except Excel
were cross-validated by using a list of pseudo-random numbers as model inputs to
ensure consistency of model outputs. PSA was conducted by sampling random
probabilities from beta distributions and replicating the model 1000 times. Ten
simulations of each base-case and PSA model type were run to assess variability in
platform efficiency. RESULTS: The speed of Excel could not be timed in the base-
case microsimulation since results were calculated instantly. VBA was slower than
R with means of 0.09 seconds and 0.02 seconds, respectively. Java generated a
system time of zero, indicating the program required 0.001s. The Excel PSA sim-
ulations required the most time with 33.4s, followed by VBA (29.4s). R required
19.0s and Java required the least amount of time (4.0s). CPU usage for PSA simula-
tions was highest with Excel (80%) and similar for all other platforms (25%).
CONCLUSIONS:With the obvious caveats that program speed is a function of com-
puting power and coding efficiency, the results of this analysis demonstrate Java
was consistently faster than Excel, VBA and R, which are commonly used for phar-
macoeconomic models. With increasing model complexity and running times, ex-
ploration of alternate implementations for their execution is recommended.
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The current recommendations for the conservative management of overactive
bladder symptoms and detrusor overactivity, given by NICE 2012, are pelvic floor
muscle training, bladder training, sacral nerve stimulation, mid-urethral tape and
antimuscarinic drugs- oxybutynin, darifenacin, solifenacin, tolterodine, and trop-
sium. More recently, emerging evidence suggests that Botulinum toxin type A is
also an effective intervention for overactive bladder and idiopathic detrusor over-
activity. Although a number of meta-analyses have been published reporting pair-
wise comparisons of the various interventions, to date no network meta-analysis
has been undertaken comparing all interventions simultaneously.OBJECTIVES: To
evaluate the clinical effectiveness of drug therapy, neuromodulation, botulinum
toxin, and behaviour therapy, in the prevention of overactive bladder symptoms
and detrusor overactivity.METHODS:Mixed treatment network meta-analyses for
the individual, and classes (i.e. behaviour, drugs etc.), of interventions using Win-
BUGS. The correlations between the interventions within a class were addressed by
conducting a mixed treatment network meta-analysis using a hierarchical model
structure. RESULTS: Evaluation of the class of interventions, i.e. ‘lumping’ individ-
ual interventions with classes, demonstrates an increased precision in the out-
come; however, categorising the interventions decreases the interpretability of the
results. At the individual intervention level, the sparseness of the data decreases
the precision of the estimates, but enables comparisons to be made between indi-
vidual interventions. The hierarchical model, allows both increased precision, due
to the utilisation of all of the available data, whilst still allowing comparisons to be
made between individual interventions both within and between classes.
CONCLUSIONS: Use of a hierarchical model increases the interpretability of the
mixed treatment network meta-analysis whilst maximising the precision in terms
of outcome. However, defining the hierarchical structure can prove difficult in
some instances, with potential comparators residing at different levels in the hi-
erarchy.
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OBJECTIVES: Cost-effectiveness studies of health technologies where data are ex-
trapolated from short term clinical trials to estimate results over appropriate de-
cision making time horizons typically assume that the decision context remains
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